This document provides the prior authorization criteria, clinical prerequisites, exclusions, documentation requirements, quantity and duration limits, step‑therapy rules, prescriber and site‑of‑care expectations, and reauthorization conditions used to adjudicate coverage for Priority Medicare Dual Premier (HMO D‑SNP) pharmacy and specialty drugs. An alphabetical index of covered drugs appears after the criterion listings and individual product sections [[chunk 1]][[chunk 180]].
Coverage decisions described here are product‑specific and generally require one or more of the following before approval: prior trials and documented failures of specified therapies, specialist prescriber or consult, diagnostic confirmation (e.g., HRCT, right heart catheterization, genetic testing), baseline labs or functional measures, and attestation of contraindications or contraindicated combinations. Many biologics and targeted therapies require documentation of prior non‑biologic therapy and prohibit concurrent use with other biologic agents, Otezla, or JAK inhibitors [[chunk 4]][[chunk 3]][[chunk 126]].
The policy sets typical initial and reauthorization durations (commonly 1–2 years depending on product), explicit quantity limits for selected products, and specific lifetime limits where applicable (for example, Oxervate limited to 8 weeks lifetime). Reauthorization nearly always requires documentation of clinical benefit compared with baseline (examples: improved ALSFRS‑R for Radicava, decreased migraine days for CGRP agents, improved labs or symptoms for many agents) [[chunk 2]][[chunk 113]][[chunk 96]][[chunk 104]].
To avoid denials, providers should submit the required supporting documentation indicated for each product entry — e.g., most recent LDL‑C and prior statin/ezetimibe therapy for Nexlizet, sputum culture and prior multidrug regimen documentation for Arikayce, HRCT for antifibrotic agents, or baseline IgE and confirmatory testing for Xolair — and attest to any required contraindication checks or combination‑therapy exclusions noted in the product criteria [[chunk 30]][[chunk 92]][[chunk 82]][[chunk 161]].